Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Current Signal: SELL (auto-tracking)
2.19% $59.27
America/New_York / 17 apr 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 2 132.69 mill |
EPS: | -5.20 |
P/E: | -11.40 |
Earnings Date: | May 02, 2024 |
SharesOutstanding: | 35.98 mill |
Avg Daily Volume: | 0.376 mill |
RATING 2024-04-17 |
---|
B- |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Neutral | |
Return On Equity: | Strong Sell | |
Return On Asset: | Sell | |
DE: | Neutral | |
P/E: | Sell | |
Price To Book: | Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | n/a | n/a | n/a | n/a | ||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -11.40 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-1.94x |
Company: PE -11.40 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
$10.75 (-81.86%) $-48.52 |
Date: 2024-04-18 |
Expected Trading Range (DAY) |
---|
$ 55.64 - 62.90 ( +/- 6.12%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-02-23 | Seehra Jasbir | Buy | 125 000 | Employee Stock Option (right to buy) |
2024-02-13 | Seehra Jasbir | Buy | 125 000 | Employee Stock Option (right to buy) |
2024-02-13 | Regnante Keith | Buy | 40 000 | Employee Stock Option (right to buy) |
2024-02-13 | Rovaldi Christopher | Buy | 150 000 | Employee Stock Option (right to buy) |
2024-02-13 | Cooper Simon Peter | Buy | 40 000 | Employee Stock Option (right to buy) |
INSIDER POWER |
---|
67.37 |
Last 96 transactions |
Buy: 1 546 013 | Sell: 365 314 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $59.27 (2.19% ) |
Volume | 0.398 mill |
Avg. Vol. | 0.376 mill |
% of Avg. Vol | 105.92 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $51.27 | N/A | Active |
---|
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, and in patients with myelofibrosis. It is also developing small molecule product candidate KER-047 that is being developed for the treatment of anemia, and is currently in Phase 1 clinical trial; and KER-012, which is in Phase 1 clinical trial to treat disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension. The company was incorporated in 2015 and is headquartered in Lexington, Massachusetts.